Literature DB >> 33536443

Association between low estrogen receptor positive breast cancer and staining performance.

Dennis Caruana1, Wei Wei2, Sandra Martinez-Morilla1, David L Rimm1,3, Emily S Reisenbichler4.   

Abstract

Estrogen receptor (ER) expression in breast carcinomas, determined by immunohistochemistry, indicates statistically significant benefit to endocrine therapy in patients with tumors expressing ER in ≥1% of tumor cells. Rare cases with low ER expression (1-10%) lead to the dilemma of treating these tumors as ER positive or negative. We hypothesize that low ER positive result from poor staining performance and that we may detect this artefact by assessing the average dynamic range of normal ducts adjacent to low ER positive tumors. Using quantitative tools, we compare the dynamic range of normal background ER expression in patients with low (1-10%) ER tumors to dynamic range of ER expression in normal epithelium from control patient populations, to determine if low ER cases are accompanied by decreased dynamic range. Low ER cases were infrequent (1% of invasive breast carcinomas). Twenty-one cases with low ER staining and two control cohorts, including a tissue microarray (TMA) of 10 benign breast sections and a group of 34 control breast carcinomas (reported as ER negative or >10% ER positive) with normal background epithelium, were digitally scanned. QuPath was utilized to quantify ER staining for each cell as the mean optical density of nuclear DAB staining. The dynamic range of ER expression in normal epithelium surrounding low ER tumors was significantly lower (range 2-240, median 16.5) than that of the benign epithelium in the control tumors (range 3-475, median 30.8; p < 0.001) and benign TMA sections (range 38-212, median 114; p < 0.001) suggesting inconsistent stainer performance.

Year:  2020        PMID: 33536443     DOI: 10.1038/s41523-020-0146-2

Source DB:  PubMed          Journal:  NPJ Breast Cancer        ISSN: 2374-4677


  2 in total

1.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  Arch Pathol Lab Med       Date:  2010-06       Impact factor: 5.534

2.  Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study.

Authors:  Flory L Nkoy; M Elizabeth H Hammond; William Rees; Tom Belnap; Braden Rowley; Steve Catmull; William Sause
Journal:  Arch Pathol Lab Med       Date:  2010-04       Impact factor: 5.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.